Mosaic ImmunoEngineering Inc. (CPMV)
USD 0.65
(-22.25%)
USD 0.65
(-22.25%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -2.38 Million USD | 35.38% |
| 2021 | -3.68 Million USD | 0.0% |
| 2019 | -798.46 Thousand USD | 0.0% |
| 2017 | -1.2 Million USD | -2565.87% |
| 2016 | -45.36 Thousand USD | 96.42% |
| 2015 | -1.26 Million USD | 17.65% |
| 2014 | -1.53 Million USD | -4.85% |
| 2013 | -1.46 Million USD | -233.81% |
| 2012 | 1.09 Million USD | 122.74% |
| 2011 | -4.82 Million USD | 58.14% |
| 2010 | -11.51 Million USD | -72.39% |
| 2009 | -6.67 Million USD | -857.77% |
| 2008 | 881.5 Thousand USD | -90.61% |
| 2007 | 9.38 Million USD | -60.37% |
| 2006 | 23.69 Million USD | -17.37% |
| 2005 | 28.67 Million USD | 1164.49% |
| 2004 | -2.69 Million USD | 35.09% |
| 2003 | -4.14 Million USD | -6.73% |
| 2002 | -3.88 Million USD | 29.14% |
| 2001 | -5.48 Million USD | -10.43% |
| 2000 | -4.96 Million USD | 33.65% |
| 1999 | -7.48 Million USD | -75.11% |
| 1998 | -4.27 Million USD | 27.45% |
| 1997 | -5.89 Million USD | -302.71% |
| 1996 | -1.46 Million USD | 38.45% |
| 1995 | -2.37 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -333.24 Thousand USD | -1799.19% |
| 2023 Q1 | -399.04 Thousand USD | 25.34% |
| 2023 Q2 | 19.61 Thousand USD | 104.91% |
| 2022 Q4 | -534.49 Thousand USD | -317.22% |
| 2022 Q2 | -929.63 Thousand USD | -21.84% |
| 2022 Q3 | 246.05 Thousand USD | 126.47% |
| 2022 Q1 | -762.97 Thousand USD | 10.27% |
| 2022 FY | -2.38 Million USD | 35.38% |
| 2021 FY | -3.68 Million USD | 0.0% |
| 2021 Q1 | -806.84 Thousand USD | -27.86% |
| 2021 Q2 | -979.42 Thousand USD | -21.39% |
| 2021 Q3 | -1.04 Million USD | -7.0% |
| 2021 Q4 | -850.26 Thousand USD | 18.86% |
| 2020 Q4 | -631.04 Thousand USD | -444.55% |
| 2020 Q2 | -102.88 Thousand USD | -1.59% |
| 2020 Q1 | -101.28 Thousand USD | 80.26% |
| 2020 Q3 | -115.88 Thousand USD | -12.63% |
| 2019 Q4 | -513.1 Thousand USD | -49.48% |
| 2019 FY | -798.46 Thousand USD | 0.0% |
| 2019 Q1 | -184.07 Thousand USD | -21.01% |
| 2019 Q2 | -249.34 Thousand USD | -35.46% |
| 2019 Q3 | -343.25 Thousand USD | -37.66% |
| 2018 Q3 | -212.91 Thousand USD | 31.17% |
| 2018 Q1 | -256.41 Thousand USD | 26.96% |
| 2018 Q2 | -309.33 Thousand USD | -20.64% |
| 2018 Q4 | -152.12 Thousand USD | 28.55% |
| 2017 Q2 | -327.4 Thousand USD | -5.84% |
| 2017 FY | -1.2 Million USD | -2565.87% |
| 2017 Q1 | -309.32 Thousand USD | -131.99% |
| 2017 Q3 | -292.66 Thousand USD | 10.61% |
| 2017 Q4 | -351.03 Thousand USD | -19.94% |
| 2016 Q4 | 967.02 Thousand USD | 357.41% |
| 2016 Q3 | -375.66 Thousand USD | 34.45% |
| 2016 Q1 | -531.86 Thousand USD | -515.45% |
| 2016 Q2 | -573.08 Thousand USD | -7.75% |
| 2016 FY | -45.36 Thousand USD | 96.42% |
| 2015 FY | -1.26 Million USD | 17.65% |
| 2015 Q4 | -86.41 Thousand USD | -14.87% |
| 2015 Q3 | -75.23 Thousand USD | 85.94% |
| 2015 Q2 | -535.19 Thousand USD | -2216.89% |
| 2015 Q1 | 25.28 Thousand USD | 105.82% |
| 2014 FY | -1.53 Million USD | -4.85% |
| 2014 Q1 | -396.01 Thousand USD | -688.84% |
| 2014 Q2 | -651.21 Thousand USD | -64.45% |
| 2014 Q3 | -593.95 Thousand USD | 8.79% |
| 2014 Q4 | -434.16 Thousand USD | 26.9% |
| 2013 FY | -1.46 Million USD | -233.81% |
| 2013 Q4 | 67.25 Thousand USD | 113.81% |
| 2013 Q3 | -486.89 Thousand USD | -128.51% |
| 2013 Q2 | 1.7 Million USD | 287.3% |
| 2013 Q1 | -911.72 Thousand USD | -176.44% |
| 2012 FY | 1.09 Million USD | 122.74% |
| 2012 Q1 | -1.24 Million USD | -24.06% |
| 2012 Q4 | 1.19 Million USD | 233.65% |
| 2012 Q2 | -1.5 Million USD | -20.84% |
| 2012 Q3 | -892.41 Thousand USD | 40.74% |
| 2011 Q3 | -1.06 Million USD | 55.04% |
| 2011 Q2 | -2.36 Million USD | 58.11% |
| 2011 Q1 | -5.64 Million USD | -276.72% |
| 2011 FY | -4.82 Million USD | 58.14% |
| 2011 Q4 | -1 Million USD | 5.59% |
| 2010 Q1 | -938.27 Thousand USD | 65.84% |
| 2010 Q2 | -1 Million USD | -7.63% |
| 2010 FY | -11.51 Million USD | -72.39% |
| 2010 Q3 | -2 Million USD | -98.09% |
| 2010 Q4 | -1.49 Million USD | 25.04% |
| 2009 Q2 | 93.6 Thousand USD | 106.28% |
| 2009 Q3 | -1.98 Million USD | -2220.74% |
| 2009 Q4 | -2.74 Million USD | -38.36% |
| 2009 FY | -6.67 Million USD | -857.77% |
| 2009 Q1 | -1.48 Million USD | -59.76% |
| 2008 Q1 | 6.29 Million USD | 160.38% |
| 2008 Q3 | 3.2 Million USD | 21.48% |
| 2008 FY | 881.5 Thousand USD | -90.61% |
| 2008 Q2 | 2.64 Million USD | -58.01% |
| 2008 Q4 | -932.25 Thousand USD | -129.05% |
| 2007 Q1 | 9.61 Million USD | 611.03% |
| 2007 FY | 9.38 Million USD | -60.37% |
| 2007 Q3 | -1.96 Million USD | -119.69% |
| 2007 Q2 | 9.96 Million USD | 3.62% |
| 2007 Q4 | 2.41 Million USD | 223.14% |
| 2006 Q1 | 24.88 Million USD | 2052.29% |
| 2006 Q3 | 5.99 Million USD | 866.8% |
| 2006 Q2 | 619.59 Thousand USD | -97.51% |
| 2006 FY | 23.69 Million USD | -17.37% |
| 2006 Q4 | -1.88 Million USD | -131.42% |
| 2005 FY | 28.67 Million USD | 1164.49% |
| 2005 Q2 | -1.17 Million USD | -278.01% |
| 2005 Q3 | 4.44 Million USD | 478.75% |
| 2005 Q1 | 658.86 Thousand USD | 161.4% |
| 2005 Q4 | -1.27 Million USD | -128.7% |
| 2004 Q2 | -1.14 Million USD | -17.71% |
| 2004 Q3 | -1.1 Million USD | 3.68% |
| 2004 FY | -2.69 Million USD | 35.09% |
| 2004 Q1 | -975.89 Thousand USD | -11.81% |
| 2004 Q4 | -1.07 Million USD | 3.01% |
| 2003 Q3 | -1.15 Million USD | -12.45% |
| 2003 Q2 | -1.02 Million USD | -21.63% |
| 2003 Q1 | -842.66 Thousand USD | 21.78% |
| 2003 FY | -4.14 Million USD | -6.73% |
| 2003 Q4 | -872.79 Thousand USD | 24.27% |
| 2002 Q1 | -1.26 Million USD | 19.11% |
| 2002 FY | -3.88 Million USD | 29.14% |
| 2002 Q4 | -1.07 Million USD | -14.19% |
| 2002 Q3 | -943.44 Thousand USD | 41.79% |
| 2002 Q2 | -1.62 Million USD | -28.57% |
| 2001 FY | -5.48 Million USD | -10.43% |
| 2001 Q1 | -1.35 Million USD | -13.99% |
| 2001 Q4 | -1.55 Million USD | -48.87% |
| 2001 Q3 | -1.04 Million USD | 32.15% |
| 2001 Q2 | -1.54 Million USD | -14.07% |
| 2000 FY | -4.96 Million USD | 33.65% |
| 2000 Q4 | -1.18 Million USD | -33.85% |
| 2000 Q3 | -886.54 Thousand USD | -11.39% |
| 2000 Q1 | -5.04 Million USD | -458.98% |
| 2000 Q2 | -795.86 Thousand USD | 84.22% |
| 1999 Q4 | -902 Thousand USD | -20.46% |
| 1999 Q3 | -748.77 Thousand USD | 0.0% |
| 1999 FY | -7.48 Million USD | -75.11% |
| 1998 FY | -4.27 Million USD | 27.45% |
| 1997 FY | -5.89 Million USD | -302.71% |
| 1996 FY | -1.46 Million USD | 38.45% |
| 1995 FY | -2.37 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -78.285% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 65.904% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 104.494% |
| Nascent Biotech, Inc. | -2.08 Million USD | -14.044% |
| Rebus Holdings, Inc. | -1.02 Million USD | -133.419% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 103.655% |
| Qrons Inc. | -789.34 Thousand USD | -201.625% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -276.477% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 96.197% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -473.042% |
| Skye Bioscience, Inc. | -37.64 Million USD | 93.675% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 96.824% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 63.795% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -770.831% |
| SQZ Biotechnologies Company | -79.46 Million USD | 97.004% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 17.685% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -30.779% |
| Mesoblast Limited | -87.95 Million USD | 97.293% |
| Marizyme, Inc. | -65.34 Million USD | 96.357% |
| Genus plc | 7.9 Million USD | 130.138% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 78.141% |
| Pharming Group N.V. | -10.54 Million USD | 77.428% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -9.727% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 35.83% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 73.079% |
| ContraFect Corporation | -65.15 Million USD | 96.346% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 51.272% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -37.825% |
| IMV Inc. | -36.48 Million USD | 93.475% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 70.46% |
| MultiCell Technologies, Inc. | -380.07 USD | -626329.342% |
| ONE Bio Corp. | 8.67 Million USD | 127.44% |
| Accustem Sciences Inc. | -3.74 Million USD | 36.449% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 95.394% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -87.894% |
| Q BioMed Inc. | -2.05 Million USD | -16.022% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 36.221% |
| Biomind Labs Inc. | -1.21 Million USD | -96.066% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 96.014% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 23.242% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 69.874% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -22.143% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -15797.903% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 84.999% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 59.072% |
| GB Sciences, Inc. | -1.36 Million USD | -74.848% |
| Alpha Cognition Inc. | -13.77 Million USD | 82.713% |
| HST Global, Inc. | -146.21 Thousand USD | -1528.391% |
| CSL Limited | 2.64 Billion USD | 100.09% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -35.68% |
| Halberd Corporation | -79.67 Thousand USD | -2888.19% |
| Enzolytics Inc. | -2.17 Million USD | -9.373% |
| Agentix Corp. | -1.37 Million USD | -73.254% |
| Resverlogix Corp. | -3.61 Million USD | 34.048% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 24.928% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.193% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 2529.459% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 134.383% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 40.074% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 21.323% |
| AVAX Technologies, Inc. | -6.41 Million USD | 62.878% |
| Zenith Capital Corp. | -10.59 Million USD | 77.53% |
| Genscript Biotech Corporation | -95.47 Million USD | 97.506% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -10143.826% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 42.573% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -3839.189% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -18.74% |
| Kadimastem Ltd | -3.3 Million USD | 28.014% |
| Helix BioMedix, Inc. | -1.05 Million USD | -125.449% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 37.657% |
| BioStem Technologies, Inc. | -8.48 Million USD | 71.934% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -439.428% |
| LadRx Corporation | 400.44 Thousand USD | 694.559% |
| Cell Source, Inc. | -5.32 Million USD | 55.257% |
| Regen BioPharma, Inc. | 1.02 Million USD | 332.619% |
| Regen BioPharma, Inc. | 1.02 Million USD | 332.619% |
| NovAccess Global Inc. | -4.76 Million USD | 50.078% |
| Affymax, Inc. | -14.42 Million USD | 83.494% |
| Itoco Inc. | -1.86 Million USD | -27.388% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 46.407% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -42.652% |
| Mobile Lads Corp. | -2.26 Million USD | -5.195% |
| CytoDyn Inc. | -49.84 Million USD | 95.223% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -2912.501% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -943.66% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -152.873% |
| SYBLEU INC | -180.3 Thousand USD | -1220.475% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -47.629% |
| International Stem Cell Corporation | -131 Thousand USD | -1717.458% |
| Bioxytran, Inc. | -4.28 Million USD | 44.372% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -4286.921% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 5.904% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 95.047% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -12.624% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -204.893% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 24.846% |
| Neutra Corp. | -233.46 Thousand USD | -919.797% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 88.266% |
| PureTech Health plc | -65.69 Million USD | 96.376% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 88.805% |
| IXICO plc | -1.17 Million USD | -102.111% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 76.016% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 95.832% |
| CSL Limited | 2.64 Billion USD | 100.09% |
| Cellectis S.A. | -103.17 Million USD | 97.692% |